BLC
VKTX icon

Brown, Lisle/Cummings’s Viking Therapeutics VKTX Stock Holding History

Brown, Lisle/Cummings’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13K Hold
400
– – ﹤0.01% 532
2025
Q4 		$14.1K Hold
400
– – ﹤0.01% 463
2025
Q3 		$10.5K Hold
400
– – ﹤0.01% 499
2025
Q2 		$10.6K Hold
400
– – ﹤0.01% 501
2025
Q1 		$9.66K Buy
400
+200
+100% +$6.32K ﹤0.01% 497
2024
Q4 		$8.05K Hold
200
– – ﹤0.01% 504
2024
Q3 		$12.7K Buy
+200
New +$11.7K ﹤0.01% 446

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Brown, Lisle/Cummings's VKTX Position: Q1 2026 in Review

Brown, Lisle/Cummings held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 400 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

Brown, Lisle/Cummings first reported a position in VKTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $14.1K in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Brown, Lisle/Cummings held 400 shares of Viking Therapeutics worth $13K as of Q1 2026.
  • Brown, Lisle/Cummings left its Viking Therapeutics share count unchanged in Q1 2026.
  • Viking Therapeutics made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #532 holding.
  • Brown, Lisle/Cummings first reported a position in Viking Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Brown, Lisle/Cummings's Viking Therapeutics position peaked at $14.1K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.